Clinical Trials Browser

Anemia, Refractory, with Excess of Blasts × ruxolitinib × 90 days × Clear all

NCT07249346 2025-12-24

Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation

Phase 2 Recruiting

Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Leukemia, Myelomonocytic, Chronic